0000950170-23-068373.txt : 20231205
0000950170-23-068373.hdr.sgml : 20231205
20231205185930
ACCESSION NUMBER: 0000950170-23-068373
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231201
FILED AS OF DATE: 20231205
DATE AS OF CHANGE: 20231205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lyon Joseph Douglas
CENTRAL INDEX KEY: 0001817838
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50679
FILM NUMBER: 231468063
MAIL ADDRESS:
STREET 1: C/O CORCEPT THERAPEUTICS INCORPORATED
STREET 2: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC
CENTRAL INDEX KEY: 0001088856
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770487658
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650.688.8803
MAIL ADDRESS:
STREET 1: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
4
1
ownership.xml
4
X0508
4
2023-12-01
0001088856
CORCEPT THERAPEUTICS INC
CORT
0001817838
Lyon Joseph Douglas
C/O CORCEPT THERAPEUTICS INCORPORATED
149 COMMONWEALTH DRIVE
MENLO PARK
CA
94025
false
true
false
false
Chief Accounting Officer
true
Common Stock
2023-12-01
4
M
false
2568
11.35
A
8422
D
Common Stock
2023-12-01
4
S
false
2568
26.00
D
5854
D
Common Stock
2023-12-04
4
M
false
2432
11.35
A
8286
D
Common Stock
2023-12-04
4
S
false
2432
26.00
D
5854
D
Common Stock
2023-12-01
4
A
false
460
25.97
A
6314
D
Common Stock
2023-12-01
4
A
false
460
0.00
A
6774
D
Stock option (right to buy)
11.35
2023-12-01
4
M
false
5000
0
D
2029-02-08
Common Stock
5000
44167
D
Includes 1,155 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023 and 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction.
The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on December 1, 2023.
In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
Fully exercisable.
/s/ Joseph Douglas Lyon
2023-12-05